News | Radiation Therapy | May 14, 2020

Developing Microbeam Radiation Therapy (MRT) for Inoperable Cancer

An innovative radiation treatment that could one day be a valuable addition to conventional radiation therapy for inoperable brain and spinal tumors is a step closer, thanks to new research led by University of Saskatchewan (USask) researchers at the Canadian Light Source (CLS).

USask PhD bio-medical engineering student Farley Chicilo at the Canadian Light Source synchrotron at University of Saskatchewan. Photo courtesy of Canadian Light Source, University of Saskatchewan

May 14, 2020 — An innovative radiation treatment that could one day be a valuable addition to conventional radiation therapy for inoperable brain and spinal tumors is a step closer, thanks to new research led by University of Saskatchewan (USask) researchers at the Canadian Light Source (CLS).

Microbeam radiation therapy (MRT) uses very high dose, synchrotron-generated X-ray beams — narrower than a human hair — to blast tumours with radiation while sparing healthy tissue. The idea is that MRT would deliver an additional dose of radiation to a tumor after maximum conventional radiation therapy has been tried, thereby providing patients with another treatment that could extend their lives.

But the longstanding questions have been: What is the optimal X-ray energy range of the MRT radiation dose that will both penetrate the thickness of the human body and still spare the healthy cells? How can the extremely high radiation doses be delivered and measured with the accuracy necessary for human treatment?

In a just-published paper in Physics in Medicine and Biology, the research team is the first to show that MRT can be scaled up for human radiation treatment. The team has identified how the radiation can be optimally delivered to ensure the safety and effectiveness of the potential human cancer treatment.

"The challenge has been to determine the ideal energy range needed so that the therapy can be used in humans with the next generation of synchrotrons," said Farley Chicilo, a USask Ph.D. student in bio-medical engineering and lead author of the paper.

The energy range that's available now at synchrotrons around the world is not sufficient to penetrate the thickness of the human body.

"We were able to identify the higher X-ray energy range needed to penetrate the thickness of the human body, validating predictions from mathematical modeling," said Chicilo, noting that mathematical modeling had indicated the optimal X-ray energy would be 150 to 250 kiloelectron volts (keV).

MRT has a key advantage over other types of radiation: because the microscopically narrow beam of bombarding X-rays is sectioned like the teeth on a comb, the unirradiated healthy tissue in the spaces between the fine microbeams is able to help heal the irradiated tissue in the microbeam path.

"For MRT to be successful, we need the parallel microbeams to be as sharply defined as possible," Chicilo said. "Imagine a tumour therapy using knife cuts so thin that they could cut completely through an animal's spinal cord, and not paralyze the animal. MRT is that thin knife cut."

The team's experiment showed that at 150 keV, the high-energy, high-intensity microbeams were not blurred, allowing the damaged cells in the microbeam path to be quickly repaired by adjacent healthy cells.

"One might think that at higher energy the electrons would scatter more and damage surrounding tissue but it's the opposite," said USask medical imaging expert Dean Chapman, Ph.D., Chicilo's co-supervisor. "This new knowledge will affect how dedicated machines for MRT will be developed in future."

Another significant challenge for scientists investigating MRT has been the lack of a detector that can accurately and precisely measure the extremely high radiation doses at micron scale resolution.

"What our team did was to develop a unique high-dose radiation measurement detector technique and use it to determine the exact radiation dose contour delivered by the microbeam," said USask engineering professor Safa Kasap, Ph.D., who has been working on X-ray imaging detectors for more than two decades and is Chicilo's supervisor.

The detector uses a special glass containing samarium, a rare Earth ion, that helped the team measure the radiation dose and ensure it is precise and controlled. The glass itself was prepared by Andy Edgar at the Victoria University of Wellington in New Zealand, a long-time collaborator of the USask group. The detector using this glass and the measurement apparatus were designed and developed at USask, the only place that uses this unique material for MRT measurement of ionizing radiation.

Samarium glows orange when excited by a blue laser, but when exposed to X-rays, the ions gain an electron and glow red. By observing the ratio of orange to red light, the team was able to measure the dose deposited at a very high resolution over the large dose range of MRT.

"This is one of the best detectors that has been developed for measuring the detailed contour of the edges of the microbeam," said Kasap.

The new-found ability to predict both an ideal energy range of X-rays and the ideal width of the microbeams for human therapy will be "critical in future for treatment planning in clinical trials," said USask adjunct professor and team member Fred Geisler, M.D., Ph.D., a nuclear physicist and neurosurgeon who is an internationally renowned expert in spinal cord injury and spinal surgery.

"These are important and exciting steps in a process to make MRT available for human cancer treatment," Geisler said, adding this could take a decade.

Synchrotrons are the only means of generating high enough strength of parallel X-rays for MRT research. The CLS is one of only a few facilities in the world that can produce microbeams with the appropriate energy range for testing biological and medical applications.

Having the CLS located on the USask campus along with the Western College of Veterinary Medicine and the Saskatchewan Cancer Agency (SCA) creates a critical mass of multi-disciplinary researchers to continue to advance MRT.

In fact, Chicilo and some of his co-authors are currently working with the SCA on a mouse model to determine when to perform MRT after standard radiation therapy has already been tried.

For more information: www.usask.ca

Related Content

MRI Targeted biopsy is performed using cognitive fusion more easily with anatomical guidance based on the radiology report. MRI targets can be identified quickly in real-time along with micro-ultrasound targets, which may have been missed on MRI.

MRI Targeted biopsy is performed using cognitive fusion more easily with anatomical guidance based on the radiology report. MRI targets can be identified quickly in real-time along with micro-ultrasound targets, which may have been missed on MRI. Image courtesy of Exact Imaging

Feature | Prostate Cancer | January 20, 2021 | By Brian Wodlinger, Ph.D.
Historically when a patient had an elevated PSA (prostate specific antigen) test their urologist would take the next
The exceptionally high dose rate of the FLASH Beam is 3,000 times higher than normal therapy treatment (300 Gray per second vs. 0.1 Gray per second, Gray being a standard unit measuring absorbed radiation). Instead of treatment over 20 seconds, an entire treatment is completed in 6 milliseconds, giving the therapy its nickname, "FLASH." Image courtesy of Brian Pogue, PhD

The exceptionally high dose rate of the FLASH Beam is 3,000 times higher than normal therapy treatment (300 Gray per second vs. 0.1 Gray per second, Gray being a standard unit measuring absorbed radiation). Instead of treatment over 20 seconds, an entire treatment is completed in 6 milliseconds, giving the therapy its nickname, "FLASH." Image courtesy of Brian Pogue, PhD

News | Linear Accelerators | January 20, 2021
January 20, 2021 — A joint team of researchers from Radiation Oncology at Dartmouth's and...
Novel Coronavirus SARS-CoV-2 Transmission electron micrograph of SARS-CoV-2 virus particles, isolated from a patient. Image captured and color-enhanced at the NIAID Integrated Research Facility (IRF) in Fort Detrick, Maryland. Credit: National Institute of Allergy and Infectious Diseases, NIH

Novel Coronavirus SARS-CoV-2 Transmission electron micrograph of SARS-CoV-2 virus particles, isolated from a patient. Image captured and color-enhanced at the NIAID Integrated Research Facility (IRF) in Fort Detrick, Maryland. Image courtesy of  National Institute of Allergy and Infectious Diseases (NIH)

News | Coronavirus (COVID-19) | January 15, 2021
January 15, 2021 — In one of the first studies to examine the impact of the...
The "US Prostate Cancer Nuclear Medicine Diagnostics Market to 2027 - Country Analysis and Forecast by Type; PET Product" report has been added to ResearchAndMarkets.com's offering. The prostate cancer nuclear medicine diagnostics market in the US was valued at $194.47M in 2019 and is expected to grow at a CAGR of 10.6% from 2020 to 2027 to reach $431.76M by 2027.

Getty Images

News | Prostate Cancer | January 13, 2021
January 13, 2021 — The ...
A study led by researchers at the UCLA Jonsson Comprehensive Cancer Center has found that magnetic resonance imaging, or MRI, frequently underestimates the size of prostate tumors, potentially leading to undertreatment.

A study led by researchers at the UCLA Jonsson Comprehensive Cancer Center has found that magnetic resonance imaging, or MRI, frequently underestimates the size of prostate tumors, potentially leading to undertreatment.

News | Prostate Cancer | January 11, 2021
January 11, 2021 — A study
Mirion Technologies, Inc., a global provider of innovative radiation detection and measurement solutions, announced that it has acquired Sun Nuclear Corporation. Sun Nuclear is the global leader in radiation oncology quality assurance, delivering patient safety solutions for diagnostic imaging and radiation therapy centers around the world.
News | Quality Assurance (QA) | January 08, 2021
January 8, 2021 — Mirion Technologies, Inc., a global provider of
RAD Technology Medical Systems (RAD) announced it is expanding its portfolio of patented modular healthcare solutions in 2021 with the introduction of a compact shielding facility designed to accommodate the latest models of low energy, self-shielded linear accelerators (linacs) that are now available worldwide. 

Image courtesy of Siemens Healthineers

News | Linear Accelerators | January 04, 2021
January 4, 2021 — RAD Technology Medical Systems (RAD) ann